CliffBio
biologic

Kovaltry

Antihemophilic Factor (Recombinant), Full Length

Loss of exclusivityMarch 2028projected — 12-year biologic exclusivity estimate
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameKovaltry
Active ingredientAntihemophilic Factor (Recombinant), Full Length
Strength1000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2016
Marketing statusRx

More from Bayer Healthcare

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kovaltry patent cliff — loss of exclusivity March 2028 | CliffBio